Subsequent Events (Details Narrative) |
9 Months Ended | ||||||||
|---|---|---|---|---|---|---|---|---|---|
|
Nov. 12, 2020
Integer
|
Nov. 11, 2020
USD ($)
$ / shares
shares
|
Oct. 31, 2020
USD ($)
$ / shares
shares
|
Aug. 13, 2020
USD ($)
|
Apr. 08, 2020
USD ($)
$ / shares
|
Mar. 23, 2020
USD ($)
|
Dec. 09, 2019
USD ($)
|
Sep. 30, 2020
USD ($)
$ / shares
|
Sep. 30, 2019
USD ($)
|
|
| Proceeds from common stock | $ 14,564,961 | ||||||||
| Warrants exercise price | $ / shares | $ 0.0001 | ||||||||
| Proceeds from warrants | $ 80 | ||||||||
| Former Members [Member] | Private Placement [Member] | |||||||||
| Proceeds from warrants | $ 1,800,000 | ||||||||
| Securities Purchase Agreement [Member] | |||||||||
| Proceeds from common stock | $ 6,847,908 | $ 4,600,002 | |||||||
| Warrants exercise price | $ / shares | $ 7.50 | ||||||||
| Subsequent Event [Member] | |||||||||
| Trading days | Integer | 10 | ||||||||
| Subsequent Event [Member] | Private Placement [Member] | |||||||||
| Proceeds from warrants | $ 18,100,000 | ||||||||
| Subsequent Event [Member] | Holder [Member] | Private Placement [Member] | |||||||||
| Warrants Description | A holder of a Warrant will not have the right to exercise any portion of its Warrants if the holder, together with its affiliates, would beneficially own in excess of 4.99% (or 9.99% at the election of the holder prior to the date of issuance) of the number of shares of Akers common stock issued and outstanding immediately after giving effect to such exercise (the "Beneficial Ownership Limitation"); provided, however, that upon 61 days' prior notice to the Company, the holder may increase or decrease the Beneficial Ownership Limitation, but in no event shall the Beneficial Ownership Limitation exceed 9.99%. | ||||||||
| Subsequent Event [Member] | Christopher C. Schreiber [Member] | |||||||||
| Bonuses Received | $ 150,000 | ||||||||
| Subsequent Event [Member] | Pre-Funded Warrants [Member] | Private Placement [Member] | |||||||||
| Stock issued during the period | shares | 9,765,933 | ||||||||
| Warrants exercise price | $ / shares | $ 0.01 | ||||||||
| Subsequent Event [Member] | Investor Warrants [Member] | Private Placement [Member] | |||||||||
| Stock issued during the period | shares | 9,765,933 | ||||||||
| Warrants exercise price | $ / shares | $ 2.06 | ||||||||
| Subsequent Event [Member] | Minimum [Member] | |||||||||
| Share price | $ / shares | $ 5.00 | ||||||||
| Subsequent Event [Member] | Katalyst Securities LLC [Member] | |||||||||
| Warrants exercise price | $ / shares | $ 1.85 | ||||||||
| Equal fee percent | 6.50% | ||||||||
| Proceeds from Issuance of Private Placement | $ 25,000 | ||||||||
| Subsequent Event [Member] | Katalyst Securities LLC [Member] | Maximum [Member] | |||||||||
| Purchase of warrants | shares | 390,368 | ||||||||
| Subsequent Event [Member] | Merger Agreement [Member] | Private Placement [Member] | |||||||||
| Proceeds from warrants | $ 25,000,000 | ||||||||
| Subsequent Event [Member] | Merger Agreement [Member] | MYMD Pharmaceuticals, Inc., [Member] | |||||||||
| Ownership percentage | 80.00% | ||||||||
| Stock issued during the period | shares | 300,000 | ||||||||
| Subsequent Event [Member] | Merger Agreement [Member] | MYMD Pharmaceuticals, Inc., [Member] | Secured Promissory Note [Member] | |||||||||
| Debt instrument, maturity date | Apr. 15, 2022 | ||||||||
| Subsequent Event [Member] | Merger Agreement [Member] | MYMD Pharmaceuticals, Inc., [Member] | Extended Maturity [Member] | |||||||||
| Debt instrument, maturity date description | The Merger Agreement contains certain termination rights for both the Company and MYMD, including, among other things, (a) Akers may, upon written notice, extend the originally scheduled End Date (defined in the Merger Agreement as April 15, 2021) to May 15, 2021 (the "Extended Date") so long as (i) Akers and Merger Sub are not then in material breach of any provision of the Merger Agreement and (ii) within three calendar days of the written request by MYMD, Akers makes an additional loan to MYMD of up to $600,000, which will have the same terms and conditions of the Note (as defined below and such additional note "Second Note") and (b) Akers may, upon written notice, extend the Extended Date to June 30, 2021, so long as (i) Akers and Merger Sub are not then in material breach of any provision of the Merger Agreement, (ii) on the effective date of such extension, the loan amount evidenced by the Note and the Second Note may, at the sole option of MYMD upon written notice to Akers, be converted into shares of MYMD common stock at a conversion price of $2.00 per share, subject to certain adjustments and (iii) Akers will, at MYMD's request, either (at the option of MYMD); (A) subscribe for 300,000 shares of MYMD common stock at a subscription price of $2.00 per share, subject to certain adjustments as set forth in the Merger Agreement, or (B) makes an additional loan to MYMD of up to $600,000, which will have the same terms and conditions of the Note (the "Third Note," and all amounts outstanding under the Note, the Second Note and the Third Note, the "Loan Amount"). In addition, if Akers terminates the Merger Agreement under certain circumstances specified therein, the Loan Amount, if any, at the sole discretion of MYMD, will be convertible into shares of common stock of MYMD at a conversion price of $2.00 per share upon delivery of written notice by MYMD to Akers within 30 calendar days after the effective date of termination of the Merger Agreement. | ||||||||
| Subsequent Event [Member] | Merger Agreement [Member] | MYMD Pharmaceuticals, Inc., [Member] | Post-Closing Shares [Member] | |||||||||
| Ownership percentage | 20.00% | ||||||||
| Subsequent Event [Member] | Merger Agreement [Member] | MYMD Pharmaceuticals, Inc., [Member] | Maximum [Member] | |||||||||
| Loans payable | $ 3,000,000 | ||||||||
| Subsequent Event [Member] | Merger Agreement [Member] | MYMD Pharmaceuticals, Inc., [Member] | Maximum [Member] | Second Note [Member] | |||||||||
| Loans payable | 600,000 | ||||||||
| Subsequent Event [Member] | Merger Agreement [Member] | MYMD Pharmaceuticals, Inc., [Member] | Maximum [Member] | Third Note [Member] | |||||||||
| Loans payable | 600,000 | ||||||||
| Subsequent Event [Member] | Merger Agreement [Member] | MYMD Pharmaceuticals, Inc., [Member] | Maximum [Member] | Secured Promissory Note [Member] | |||||||||
| Loans payable | $ 3,000,000 | ||||||||
| Debt instrument, interest rate | 5.00% | ||||||||
| Subsequent Event [Member] | Merger Agreement [Member] | MYMD Pharmaceuticals, Inc., [Member] | Minimum [Member] | |||||||||
| Share price | $ / shares | $ 5.00 | ||||||||
| Subsequent Event [Member] | Securities Purchase Agreement [Member] | Accredited Investors [Member] | |||||||||
| Share price | $ / shares | $ 1.85 | ||||||||
| Stock issued during the period | shares | 9,765,933 | ||||||||
| Proceeds from common stock | $ 18,100,000 | ||||||||